an excellent AlloPAX Generic Name: levocetirizine dihydrochloride, loratadine Dosage Form: topical application Print this page Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. Each Allo PAX provides 3 grams of Levocetirizine dihydrochloride, 3 grams Loratadine USP, and 54 grams of Base. The resulting mixture is intended for transdermal use. For Prescription Use Only Distributed by: PharmaGenetico LLC San Antonio, TX 78257 AlloPAX levocetirizine dihydrochloride 5%, loratadine 5% kit Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:69817-0201 Packaging # Item Code Package Description 1 NDC:69817-0201-1 1 KIT in 1 BOX Quantity of Parts Part # Package Quantity Total Product Quantity Part 1 1 BOTTLE, PLASTIC 3 g in 3 Part 2 1 BOTTLE, PLASTIC 3 g in 3 Part 3 1 JAR 54 g in 54 Part 1 of 3 LORATADINE loratadine powder, for suspension Product Information Route of Administration TRANSDERMAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LORATADINE (LORATADINE) LORATADINE 3 g in 3 g Packaging # Item Code Package Description 1 3 g in 1 BOTTLE, PLASTIC Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date unapproved drug other Part 2 of 3 LEVOCETIRIZINE DIHYDROCHLORIDE levocetirizine dihydrochloride powder, for suspension Product Information Route of Administration TRANSDERMAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOCETIRIZINE DIHYDROCHLORIDE (LEVOCETIRIZINE) LEVOCETIRIZINE DIHYDROCHLORIDE 3 g in 3 g Packaging # Item Code Package Description 1 3 g in 1 BOTTLE, PLASTIC Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date unapproved drug other Part 3 of 3 CREAM BASE cream base cream Product Information Route of Administration TRANSDERMAL DEA Schedule Inactive Ingredients Ingredient Name Strength WATER ISOPROPYL MYRISTATE LECITHIN, SOYBEAN CETOSTEARYL ALCOHOL WHEAT GERM OIL CETYL ALCOHOL STEARYL ALCOHOL POLYOXYL 20 CETOSTEARYL ETHER GLYCERIN DIMETHICONE C13-14 ISOPARAFFIN LAURETH-7 XANTHAN GUM MAGNESIUM ALUMINUM SILICATE EDETATE DISODIUM BUTYLATED HYDROXYTOLUENE PHENOXYETHANOL METHYLISOTHIAZOLINONE METHYLCHLOROISOTHIAZOLINONE POLYACRYLAMIDE (10000 MW) MEDIUM-CHAIN TRIGLYCERIDES Packaging # Item Code Package Description 1 54 g in 1 JAR Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date unapproved drug other Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date unapproved drug other 06/30/2015 Labeler - PharmaGenetico LLC (079713987) Establishment Name Address ID/FEI Operations Mission Pharmacal Company 927726893 manufacture(69817-0201) Revised: 07/2017 PharmaGenetico LLC FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Recently Approved Lonhala Magnair Lonhala Magnair (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) bronchodilator for... Ozempic Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog administered once-weekly for the... Ogivri Ogivri (trastuzumab-dkst) is a HER2 / neu receptor antagonist biosimilar to Herceptin indicated for... Sublocade Sublocade (buprenorphine) is a once-monthly injectable partial opioid agonist formulation for the... More worried
place of work AlloPAX locate
EmoticonEmoticon